Exploring the nanobody patent landscape: a focus on BCMA sequences and structural analysis

Area of Science:

• Biotechnology
• Immunology
• Pharmaceutical Sciences

Background:

• Nanobodies (Nbs), derived from heavy-chain-only antibodies, show significant therapeutic potential.
• Rapid advancements in Nb development necessitate a comprehensive understanding of the patent landscape.

Purpose of the Study:

• To conduct a comprehensive patent landscape analysis of nanobody technologies.
• To identify innovation trends, novel drug candidates, and opportunities/challenges in nanobody research, development, and commercialization.
• To analyze patented nanobody sequences targeting B-cell maturation antigen (BCMA) for drug design and patent strategy.

Main Methods:

• Patent landscape analysis of nanobody technologies.
• Patent sequence analysis of nanobody drugs, focusing on B-cell maturation antigen (BCMA).
• Evaluation of features, physicochemical properties, modification sites, and epitope-binding tendencies of patented nanobodies.

Main Results:

• Identification of key innovation trends in nanobody technology.
• Characterization of patented nanobody sequences, including those targeting BCMA.
• Analysis of structural-level patent protection importance for nanobody design and validation.

Conclusions:

• The study provides valuable insights into nanobody drug development.
• Findings support strategic decision-making in patenting and commercialization of nanobody therapeutics.
• Offers a theoretical foundation for nanobody design and experimental validation based on patent data.